FTC claims a win as Teva moves to delist hundreds of patents from FDA Orange Book, agency says
After pressure from the FTC, Teva has asked the FDA to delist hundreds of patents on products for asthma, diabetes, chronic obstructive pulmonary disease and for epinephrine autoinjectors, the agency said.